Is Jaguar Health Inc (NASDAQ: JAGX) Back In The Buying Zone?

Currently, there are 208.77M common shares owned by the public and among those 165.52M shares have been available to trade.

The company’s stock has a 5-day price change of 13.80% and -44.85% over the past three months. JAGX shares are trading -40.62% year to date (YTD), with the 12-month market performance down to -88.47% lower. It has a 12-month low price of $0.05 and touched a high of $1.22 over the same period. JAGX has an average intraday trading volume of 37.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.74%, 5.79%, and -70.32% respectively.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Institutional ownership of Jaguar Health Inc (NASDAQ: JAGX) shares accounts for 0.59% of the company’s 208.77M shares outstanding.

It has a market capitalization of $18.77M and a beta (3y monthly) value of 1.32. The earnings-per-share (ttm) stands at -$6.88. Price movements for the stock have been influenced by the stock’s volatility, which stands at 14.89% over the week and 21.98% over the month.

Analysts forecast that Jaguar Health Inc (JAGX) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2024. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$9 a year ago. EPS should shrink at an annualized rate of 40.00% over the next five years, compared to 80.25% over the past 5-year period.

Looking at the support for the JAGX, a number of firms have released research notes about the stock. Cantor Fitzgerald stated their Overweight rating for the stock in a research note on July 07, 2021, with the firm’s price target at $5. Rodman & Renshaw coverage for the Jaguar Health Inc (JAGX) stock in a research note released on July 11, 2017 offered a Buy rating with a price target of $2.

Most Popular

Related Posts